Letters to the Editor

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes

Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
National Taiwan University Cancer Center, Taipei
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Phoenix, Arizona
Division of Hematology, Mayo Clinic, Phoenix, Arizona
Division of Hematology, Mayo Clinic, Phoenix, Arizona
Division of Hematology, Mayo Clinic, Phoenix, Arizona
Division of Hematology, Mayo Clinic, Phoenix, Arizona
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville
Haematologica Early view Jan 8, 2026 https://doi.org/10.3324/haematol.2025.289268